Fairvalue-Calculator Fairvalue-Calculator
EN DE

Samjin Pharmaceuticals Co (005500) Fair Value & Analysis

Healthcare · KR · Market cap 237B KRW

Price18,200 KRW
Fair Value30,402 KRW
Upside+67.0%
Quality95/100
Evidence: High Range 20,922 KRW – 45,720 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Samjin Pharmaceuticals Co (005500) currently trades at 18,200 KRW, while our model-based Fair Value estimate is 30,402 KRW — implying the stock looks roughly 67.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Ko…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% United Therapeutics Corporation (U2TH34) -2%

Frequently asked questions

Is Samjin Pharmaceuticals Co (005500) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 30,402 KRW versus a price of 18,200 KRW — about +67% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 005500?
Our 21-model fair value for Samjin Pharmaceuticals Co is 30,402 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 18,200 KRW.
What is the quality score of 005500?
Samjin Pharmaceuticals Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.